PURPOSE: To evaluate the use of high-dose busulfan (HDB) with autologous bone marrow transplantation (ABMT) in patients with myeloma. PATIENTS AND METHODS: Fifteen patients received HDB (16 mg/kg), eight of whom received high-dose melphalan (HDM) but had experienced a short remission or progression-free interval. Two patients had received HDM on two previous occasions, one had no response to low-dose melphalan, and four had impaired renal function (edathamil clearance < 40 mL/min). All patients received induction chemotherapy before HDB. RESULTS: Two patients were in complete remission (CR) after induction chemotherapy before HDB. Of the remaining 13 patients, four (31%) achieved CR and two (15%) achieved a partial remission for an overall response rate of 46%. There were three treatment-related deaths, but the toxicity was otherwise predictable and manageable. CONCLUSIONS: In heavily pretreated patients, HDB results in a relatively high response rate. It can also be used safely in patients with renal impairment who are not suitable for HDM.
PURPOSE: To evaluate the use of high-dose busulfan (HDB) with autologous bone marrow transplantation (ABMT) in patients with myeloma. PATIENTS AND METHODS: Fifteen patients received HDB (16 mg/kg), eight of whom received high-dose melphalan (HDM) but had experienced a short remission or progression-free interval. Two patients had received HDM on two previous occasions, one had no response to low-dose melphalan, and four had impaired renal function (edathamil clearance < 40 mL/min). All patients received induction chemotherapy before HDB. RESULTS: Two patients were in complete remission (CR) after induction chemotherapy before HDB. Of the remaining 13 patients, four (31%) achieved CR and two (15%) achieved a partial remission for an overall response rate of 46%. There were three treatment-related deaths, but the toxicity was otherwise predictable and manageable. CONCLUSIONS: In heavily pretreated patients, HDB results in a relatively high response rate. It can also be used safely in patients with renal impairment who are not suitable for HDM.
Authors: B Sirohi; R Powles; J Mehta; J Treleaven; N Raje; S Kulkarni; C Rudin; N Bhagwati; C Horton; R Saso; S Singhal; R Parikh Journal: Med Oncol Date: 2001 Impact factor: 3.064
Authors: Juan José Lahuerta; Maria Victoria Mateos; Joaquin Martínez-López; Carlos Grande; Javier de la Rubia; Laura Rosiñol; Anna Sureda; José García-Laraña; Joaquín Díaz-Mediavilla; Miguel T Hernández-García; Dolores Carrera; Joan Besalduch; Felipe de Arriba; Albert Oriol; Lourdes Escoda; Javier García-Frade; Concepción Rivas-González; Adrían Alegre; Joan Bladé; Jesús F San Miguel Journal: Haematologica Date: 2010-07-27 Impact factor: 9.941
Authors: G Vassal; S Koscielny; D Challine; D Valteau-Couanet; I Boland; A Deroussent; J Lemerle; A Gouyette; O Hartmann Journal: Cancer Chemother Pharmacol Date: 1996 Impact factor: 3.333
Authors: Qaiser Bashir; Peter F Thall; Denái R Milton; Patricia S Fox; Jitesh D Kawedia; Partow Kebriaei; Nina Shah; Krina Patel; Borje S Andersson; Yago L Nieto; Ben C Valdez; Simrit Parmar; Gabriela Rondon; Ruby Delgado; Chitra Hosing; Uday R Popat; Betul Oran; Stefan O Ciurea; Pei Lin; Donna M Weber; Sheeba K Thomas; Hans C Lee; Elisabet E Manasanch; Robert Z Orlowski; Loretta A Williams; Richard E Champlin; Muzaffar H Qazilbash Journal: Lancet Haematol Date: 2019-03-22 Impact factor: 30.153
Authors: B Sirohi; R Powles; S Kulkarni; C Rudin; R Saso; A Rigg; C Horton; S Singhal; J Mehta; J Treleaven Journal: Br J Cancer Date: 2001-08-03 Impact factor: 7.640
Authors: Tulio E Rodriguez; Parameswaran Hari; Patrick J Stiff; Scott E Smith; Danielle Sterrenberg; David H Vesole Journal: Biol Blood Marrow Transplant Date: 2016-05-07 Impact factor: 5.742